REGN Price Prediction Next Week
Analysis and Insights
News Impact Analysis:
Positive Trial Results for Dupixent:
Regeneron announced successful results from the ADEPT Phase 2/3 trial for Dupixent in treating adults with moderate-to-severe bullous pemphigoid. The trial met all primary and key secondary endpoints, demonstrating sustained disease remission in 20% of patients compared to 4% with placebo. This is a significant positive catalyst for REGN, as it positions Dupixent to become the first targeted therapy for this condition.Regulatory Progress:
The FDA accepted Dupixent's application for Priority Review, with a decision expected by June 20, 2025. This adds to the positive momentum and could drive further upside for REGN in the coming months.
Technical Analysis:
- Current Price: $707.75
- RSI (6, 12, 14): 61.90, 55.51, 54.30 (neutral, no overbought/oversold signals).
- MACD: Slightly negative but with a positive histogram, indicating potential bullish divergence.
- Bollinger Bands: Price is near the upper band, suggesting short-term overbought conditions.
- Fibonacci Levels:
- Pivot: $703.79
- Resistance Levels: $729.19, $744.89
- Support Levels: $678.39, $662.69
Price Prediction and Recommendation:
Based on the positive news flow and technical analysis, REGN is expected to rise to $725 next week. However, the stock may face resistance at $729.19, limiting further upside.
Buy Recommendation:
- Target Price: $725
- Stop-Loss: $678
The stock is expected to trend upward due to the positive trial results and regulatory progress, but traders should be cautious of short-term overbought conditions.
REGN Similar Chart Price Prediction
The price of REGN is predicted to go up -15.84%, based on the high correlation periods with AVXL. The similarity of these two price pattern on the periods is 90.6%.
REGN
AVXL
Down: -15.84%Similarity: 90.6%
REGN Stock Forecast & Prediction For Years 2025, 2026, 2027, 2028, 2029 and 2030
Year
REGN Price Forecast($)
Potential Return(%)
2025
712.500
-0.790
2026
1,050.000
50.270
2027
1,050.000
50.270
2028
1,200.000
71.740
2029
1,200.000
71.740
2030
1,500.000
114.670
What is REGN stock price prediction 2025 ?
What is REGN stock price prediction 2026 ?
What is REGN stock price prediction 2027 ?
What is REGN stock price prediction 2028 ?
What is REGN stock price prediction 2029 ?
What is REGN stock price prediction 2030 ?
REGN Revenue Forecast
REGN EPS Forecast
REGN FAQs
What is REGN revenue forecast for next quarter？
What is REGN eps forecast for next quarter？
REGN VS S&P500
Eylea has become the leading franchise in wet AMD and other ophthalmology markets because of its similar efficacy and more convenient dosing regimen compared with Lucentis and Avastin.
Dupixent's solid launch in severe atopic dermatitis and asthma is extending to several other allergy-related indications and COPD.
Positive early data for several bispecific antibodies in blood cancer and solid tumors supports the potential of Regeneron's in-house oncology program.
REGN Analyst's Forecast
Trung Huynh
UBS
Strong Buy → Hold
2025-01-16
Price Target
$1,130 → $738
Upside
+6.46%
UBS downgraded Regeneron to Neutral from Buy with a price target of $738, down from $1,130. The firm believes there is a disconnect between the market's shorter-term focus on Eylea revenues versus Regeneron's focus on building a long-term sustainable business. Eylea high dose adoptions are still limited at this stage, and with the backdrop of branded and biosimilar competition, UBS does not expect an inflection in the near-term., the analyst tells investors in a research note. The firm models a 14% decrease in Eylea franchise revenue in 2025, which is 4% below consensus. UBS believes the stock's current valuation justifies its base business and pipeline opportunities, and expects investors to opt for names with higher short-term growth and more value-inflecting readouts in 2025.
Geoff Meacham
Citigroup
Hold
2025-01-14
Price Target
$895 → $795
Upside
+15.07%
Srikripa Devarakonda
Truist Securities
Strong Buy
2025-01-08
Price Target
$1,126 → $1,004
Upside
+36.86%
